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Abstract
Background: Infertility is a common problem in testicular cancer. Affected men often
decide to undergo sperm banking before chemo/radiotherapy. The cumulative effects
of therapy can considerably reduce fertility.
Objective: Testicular cancers impair fertilizing ability, even before diagnosis. This study
tries to verify individual traits and semen quality in patients with testicular cancer.
Materials and Methods: This observational study analyzed 190 semen of patients
with testicular cancer (16 to 47 yr old) referred to the sub-fertility laboratory at the St.
Mary hospital for semen banking prior to treatment carcinoma. Several aspects of their
semen analyses were examined. The cases were divided into four different categories:
seminoma, teratoma, mixed germ cell tumors and others.
Results: The results showed that 23 cases were azoospermic, and 13 of the patients
who were not azoospermic, their sperm of “normal” morphology were too few to count.
Among patients that could produce spermatozoa, 59.4% had a sperm concentration of
< 20 × 106/ml. The mean of “motility excellent” and “sluggish” taken together in all
the cases was 47.2%. More than 92% of the patients had an abnormal morphology.
The morphology of sperm is the most sensitive semen parameter that is affected by
testicular carcinoma.
Conclusion: Abnormal spermatogenesis is seen in most patients with testicular cancer
before treatment with radiation, chemotherapy, or surgery. The causes of poor semen
quality in cancer patients are not well-understood, but the patients with impaired
spermatogenesis should have precise examination to find out the correct diagnosis
of problem and preserve the fertility before any treatment.
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1. Introduction
Testicular cancer is often cited as the most
common cancer of young men and boys between
15 and 35 years of age (1). It is a relatively rare tumor,
comprising only 1% of all malignant neoplasms in
men (2). The statistics reviews across Europe and
the United States show that it is increasing in
incidence in Caucasian men (3-4). An unexplained
rise in the occurrence of testicular cancer has been
observed in theUnited States, with a 100% increase
in the number of reported cases since 1936 (2).
A similar trend has also been reported in several
northern European countries. There is extensive
geographical variation and the incidence rate of
testicular cancer can fluctuate between countries
(5).
Testicular tumors can be categorized into germ
cell and non-germ cell tumors. Germ cell tumors
arise from spermatogenic cells and comprise 95%
of testicular neoplasms. Only 10% of cases of these
tumors are malignant. Non-primary tumors such as
lymphoma, leukemia, and metastases can also be
presented as testicular masses (6).
Testicular cancers (TC) impair fertilizing
ability, even before diagnosis (7). They affect
the hypothalamic-pituitary-gonadal axis and
consequently disturb spermatogenesis (8). These
deleterious effects are dependent on the stage
and type of seminoma, resulting in poor semen
quality or even azoospermia (9). In many TC
patients, sperm quality is already abnormal and
may even lack viable spermatozoa at the time of
diagnosis (10). The treatment for this type of cancer,
usually performed by surgery, chemotherapy, or
radiotherapy, further affects semen quality (9) and
hormonal function (11), thus highly impairing male
fertility. In fact, after cancer therapy, patients may
become temporarily or permanently infertile (12).
For that reason, it is strongly recommended that
men diagnosed with TC undergo sperm banking
to increase the probability of fatherhood in the
future.
Semen analysis is a preliminary assessment
of male infertility and can be done for several
reasons such as unexplained infertility, screening
sperm donors, examination of a male partner prior
to reversal of female sterilization, post-vasectomy
reversal, or assessment of patients banking semen
before undergoing chemo/radiotherapy. In these
patients, the preservation of male fertility is usually
done through cryopreservation. This procedure
stabilizes the cells at cryogenic temperatures,
which is known as a useful aspect of cryobiology
or continuation of life at low temperatures (13).
Previous study has not yet recognized whether
TC histology may clarify different alterations to
semen quality. Some researchers show that a
nonseminoma usually effects more negatively on
semen quality than a seminoma, but others fail to
prove this difference (14).
While much has been progressed in the
treatment and diagnosis of TC, knowledge
about these patients is still needed to better
understand their current lifestyles and future
decision. Therefore, this is important to examine
carefully men with impaired semen analysis.
Therefore, this study sets out to prove individual
characters and semen quality in patients with
testicular cancer, and to compare semen quality in
them.
2. Materials and Methods
2.1. Sample collection and delivery
In the current observational study, 190 semen
samples from men with TC were collected after a
minimumof 48 hr, but not longer than seven days of
sexual abstinence. Patients suffering from systemic
disorders like diabetes, hypertension, etc. were
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excluded from the study. To diminish the variability
of semen analysis results, the number of days of
sexual abstinence was kept constant as possible.
Ideally, the specimen was passed in a private room
close to the laboratory or it was delivered to the
laboratory within 1 hr of collection.
Semen specimens were passed through
masturbation and ejaculated directly into a 60
ml jar made of glass or plastic. It was warm, and
kept at room temperature (25°C) to avoid reduction
in sperm motility. All products were assessed for
the absence of spermicidal properties prior to use.
2.2. Initial examination
According to theWHOprotocol, fresh specimens
passed on the premises were placed in an
incubator at 37°C until complete liquefaction had
taken place. A normal semen sample liquefies
within 60 min at room temperature, although
usually this occurs within 15 min.
The semen sample was examined immediately
after liquefaction or within 1 hr of ejaculation, first
by simple inspection at room temperature.
The viscosity, sometimes referred to as
consistency, of the liquefied sample was
recognized as being different from coagulation.
The pH was measured at a uniform time within 1 hr
of ejaculation.
During the initial microscopic investigation of the
sample, estimates were made of the concentration,
motility, agglutination of spermatozoa and
presence of cellular elements other than
spermatozoa.
2.3. Preparation for routine semen
analysis
The volume of semen and the dimensions
of the coverslip were standardized so that the
analyses were always carried out in a preparation
of a fixed depth of about 20 μm. A fixed volume
of 10 μl semen was delivered onto a clean
glass slide with a positive displacement pipette
and covered with a 22 × 22 mm coverslip.
The freshly made wet preparation was left to
stabilize for approximately 1 min. Since sperm
motility and velocity are highly dependent
on temperature, the assessment of motility is
preferably performed at 37°C, using a warmed
stage.
At least five microscopic fields
were systematically scanned until
the motility of 200 sperm had been
graded.
The length of a normal sperm head is defined
as 4-5 μm, and for the purposes of motility
assessment, sperm moving progressively
at more than 5 head lengths/second can
be defined as grade a. The count of 200
spermatozoa was repeated on a separate 10
μl specimen from the same semen sample
and the percentages in each motility grade
from the two independent counts were
compared.
Each group of patients were compared with
each of the rest using the “Independent sample
test” and “Analysis of variance” was used to
determine the significance of the differences
between all the groups. The way in which the
mean value of a variable was affected by the
classification of the data could be determined
by analysis of variance. The one-way analysis of
variance is a generalization of the independent
sample test (for the comparison of the means
of two groups of data), and is appropriate for
any number of groups. Rather than examining
the difference between the means directly,
analysis of variance looks at the variability of the
data.
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2.4. Ethical consideration
The project was approved by the ethical
committee of Manchester University (ref 03238).
3. Results
In the semen analyses, samples were obtained
from 190 patients that were referred to the sub-
fertility department of St. Mary hospital, UK, with
diagnoses of testicular cancer.
The different types of testicular carcinoma in
190 patients consisted as 19 mixed germ cell
tumour cases (10%), 88 Seminoma cases (46.3%),
58 Teratoma cases (30.5%), and 25 other types of
tumour cases (13.2%).
The patients could be categorized by their
pathological diagnosis into four groups, seminoma,
teratoma, mixed germ cell tumor, and other types
of tumor (i.e. embryonal carcinoma, yolk sac tumor,
etc.)
The age range of the volunteers was between
21-40 yr, and the mean age was 31.38 yr. While,
the age range of the patients was 16-47 yr with the
mean age as 29.75 yr and the median was 29 yr
(Figure 1).
Patients diagnosed with mixed germ cell tumor
were in the bracket of 18-40 yr. Patients in the
seminoma group were in the 20-47 yr, while
patients in the teratoma group were in the bracket
of 16-41 yr. The mean age in the teratoma group
was 26.5 yr. The patients whose carcinoma was
categorized as ‘other types of tumor’ were in a
group with an age range of 18-41 yr, with the mean
age being 29.80 yr.
The collected data for all the patients show that
in 102 cases, information for the side of the tumor
was missing, and there is not enough evidence
to support a subsequent determination on to the
side upon which testes occupied by the tumor lay.
Among the rest of the patients, in 42 cases the
tumor was of the left testis, and in 46 of them,
the tumor was of the right testis. Table I shows
the sidedness of the tumors in different types of
testicular cancer.
The mean volume of the semen samples for
the volunteers was 3.81 ml (range 2.5-8.5 ml). The
mean volume for the whole group of patients was
2.6 ml. The lowest volume among all the patients
was 0.3 ml and the highest volume was 10 ml. The
lowest volume, which is 0.3 ml, belonged to one of
the patient in the seminoma group and the highest
volume (10 ml) belonged to a patient in the group
diagnosed with mixed germ cell tumor.
Sixty patients with various type of testicular
cancer had subnormal semen volume compared
to the WHO (1999) reference range: 5 cases with
mixed germ cell tumor (8%), 31 with seminoma
cases (52%), 15 teratoma (25%), and 9 other types
of tumor (15%).
The mean of the sperm population in volunteers
was 111.5×106/ml. Out of the 190 semen samples
derived from the patients from different groups, 10
samples had no sperm concentration at all. The
sperm count in these patients was nil and theywere
considered to have azoospermia.
The mean sperm concentration of all cases
with testicular cancer was 24.7 × 106/ml without
azoospermic patients.
The minimum sperm count in those patients,
who were producing spermatozoa was 0.09 ×
106/ml and the maximum sperm count was 167 ×
106/ml; 73 patients of the total had a normal sperm
concentration with a mean sperm count of 49.3
× 106/ml and 117 patients had an abnormal sperm
concentration with a mean of 7.26 × 106/ml. Table
II summarizes the sperm concentration in various
types of testicular cancer.
In the group containing volunteers, the mean
of “motility excellent” was 35.2%, with a minimum
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of 25% and a maximum of 50%. All of the
volunteers had 25% or more “motility excellent”.
Also, in the same group, the mean of “motility
excellent” and “motility sluggish” together was
65.8%. The immotile sperm had a mean of 25.4%,
with minimum and maximum percentages of 15%
and 40%, respectively.
The comparison of the results in cases with
the reference range that is recommended
by WHO showed that only 10 patients
(52.6% of the total) had a normal motility.
The mean of the “excellent motility” and
“excellent motility” and “sluggish motility”
together in this group was 49.9% and 62.4%,
respectively.
In the seminoma group, the mean of excellent
motility was 33.41%. Of this group, seven patients
(8%) had no spermatozoa with “excellent” motility
and 30.7% of all the patients had an “excellent”
motility of < 25%. In the seminoma group, 41
patients (46.59%) had a normal motility with a mean
of 50.49% for “excellent motility” and 62.54% for
“motility excellent” and “sluggish” together.
The mean of “excellent motility” in the teratoma
group was 34.67% with two patients having no
spermatozoa with “excellent” motility. In this group,
25.9% of the patients had an “excellent” motility of
< 25%, and 46.6% of them had “motility excellent”
and “sluggish” together of < 50%.
In the group of patients with diagnoses of other
types of testicular cancer, the mean of “excellent”
motility was 34.44%, and three patients in this
group (12% of the total in this group) had no
spermatozoa with “excellent” motility.
Table III shows the mean of motility sluggish,
motility non-progressive, and motility immotile in
various types of testicular cancer.
In the group of volunteers, the normal
morphology of sperm started from 50% and
rose to 72%. Therefore, all of the cases had normal
morphology of > 15% and the mean of normal
morphology in this group was 65.7%. In the group
of patients, 23 cases had morphology equal to 0 as
10 of them were azoospermic patients (i.e., without
any production of spermatozoa) and in a further 13
patients, who were not azoospermic, their sperm
of “normal” morphology were too few to count.
Therefore, including all of these cases, the mean
morphology for the patients was 6.55% with a
maximum of 36%. In the whole group of patients,
only 15 had a normal morphology which was 15%
or more. More than 92% of the patients had an
abnormal morphology. The mean of morphology in
the patients with “normal morphology” was 18.07%
and the mean for the patients with “abnormal
morphology” was 5.57%.
In the teratoma group, among the non-
azoospermic patients, the mean of morphology
was 6.64% and > 91% of the patients had an
“abnormal” morphology. In the group of patients
diagnosed with mixed germ cell tumor, the
mean of morphology was 8.5% and 77.8% of the
patients with “abnormal” morphology. The mean
of morphology in the patients diagnosed with
other types of carcinoma was 5.23%, of which
three patients, equal to 13.6% of the patients in this
group, had too few normal sperm to count. Also, all
of the patients in this group had “abnormal” sperm
morphology.
Table I. The sidedness of the tumors in different types of testicular cancer
Diagnosis Number of cases Missing information Left testis Right testis
Mixed germ cell tumor 19 5 7 7
Other types of testicular tumor 25 16 3 6
Teratoma 58 36 11 11
Seminoma 88 45 21 22
Data presented as numbers
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Table II. A comparison of sperm concentration in different types of testicular cancer
Diagnosis S T M O
Total number of cases 88 58 19 25
Number of patients with azoospermia 4 2 1 3
Mean sperm concentration in all of the patients (×106/ml) 22.4 23.4 30.2 21.5
Minimum sperm concentration in non-azoospermic, patients (×106/ml) 0.09 0.1 1 0.2
Highest sperm concentration in non-azoospermic, patients (×106/ml) 105 167 133 164
Percentage of the patients with subnormal sperm concentration (< 20 ×
106/ml)
60.2 62.1 57.9 68
Percentage of the patients with azoospermia 4.5 3.4 5 12
Total number of non-azoospermic patients 84 56 18 22
Percentage of the patients with subnormal sperm concentration in
non-azoospermic patients (< 20 × 106/ml)
58.3 60.7 55.6 63.6
Mean of sperm concentration in non-azoospermic patients (×106/ml) 23.5 24.2 31.8 24.4
Mean of sperm concentration in the patients with normal sperm
concentration (×106/ml)
45.2 49.3 64.7 51.5
Mean of sperm concentration in the patients with subnormal sperm
concentration (×106/ml)
7.45 7.56 5.07 7.44
Minimum sperm concentration in patients with normal sperm
concentration (×106/ml)
20 20 31 20
S: Seminoma; T: Teratoma; M: Mixed germ cell tumor; O: Other types of testicular tumor
Table III. The mean of motility sluggish, non-progressive, and immotile in various types of testicular cancer
Testicular cancer Mean of sluggish motility Mean of non-progressive motility Mean of immotile
Seminoma 13.68 5.74 42.63
Teratoma 12.59 7.07 42.22
Mixed germ cell tumor 12.05 3 41.89
Other types of carcinoma 11.28 3.32 38.96







































































Figure 1. Distribution of patients by their age in testicular cancer (count *106).
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4. Discussion
Assessment of male infertility is based mainly
on the standard semen analysis, which includes
sperm count, motility, and sperm morphology.
This study was undertaken with semen analyses
of 190 patients who had been referred to the
sub-fertility laboratory at the St Mary hospital, for
semen banking. Based on the standard procedure
recommended by WHO (1999), several aspects
of their semen analyses were examined. The
preliminary diagnosis in all of the cases was
testicular tumor. Initial statistical analysis revealed
that they were a suitable group for analysis as
their age mean (29.75), median (29), and mode
(28) were closely similar.
The cases were divided into four categories:
seminoma, teratoma, mixed germ cell tumors and
other types of tumor (i.e., embryonal carcinoma,
yolk sac tumor). The results of the semen
analyses were studied and categorized. The
variables in this study were age, volume (in ml),
population of sperm (million/ml), motility of sperm
(assessed as excellent, sluggish, non-progressive
or immotile), total sperm count (million/ejaculate),
and morphology. These variables were used as
their normal ranges have been specified by WHO.
In choosing a control group for comparison
with the patients’ results, consideration had to
be given to the very important role played by
the variable of age, because most patients with
testicular carcinoma are young. Analysis of the
data was in agreement with the finding of Gandini
et al. (15), who found that the mean age of the
seminoma patients differed from the mean age
of patients with other types of testicular cancer
and that the mean age of their seminoma patients
was significantly higher than that of the groups
of patients with embryonal carcinoma and mixed
tumors. In contrast, Botchan et al. (16) found
no mean age difference between patients with
different types of testicular cancer which is not
in agreement with the finding of this present
study.
This significant difference suggests that the age
range of the teratoma patients started earlier than
that for seminoma patients and that the patients
with the teratoma were usually younger than the
patients with the seminoma. This finding was in
agreement with some previous studies (16, 17). In
the seminoma group, no patients was under 20
yr old, and 17 patients (19%) were older than 37
yr of age. The second significant difference was
between the teratoma group and the volunteers.
Dunnett t tests treated the volunteer group as
the control group and compared all other groups
against it. In this comparison, the teratoma group
was the only group that differed significantly from
the volunteers. In each group, the correlation
of age and other variables was checked and
only one significant correlation was found in the
teratoma group. In this, the age was correlated
with the total sperm count. In the teratoma
group, as the patients got older, the total sperm
counts were increased. This finding suggests
that the effect of the teratoma in the patients
of younger age could be more serious than in
the older patients. Although, the concentration
of the sperm and the volume of the semen did
not show any significant correlation with age in
the teratoma group, the correlation of the age
and the total sperm counts indicates that both
the volume of the ejaculate and concentration
of the sperm were affected by the carcinoma
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and that this resulted in a significant correlation
between the age and the total sperm counts
(16).
Of the 190 patients, the mean semen volume
was 2.6ml, which according to theWHO reference
range is an acceptable semen volume. This finding
was in agreement with those of Panidis et al.,
who found that there was no significant difference
between themean semen volume of their patients
with testicular carcinoma and their control group
of normal fertile men (18). Also, the findings of this
present study are very similar to the findings of the
studies of Bussen et al., who found that the mean
semen volume for their patients with testicular
cancer was 2.5 ml and 2.8 ml, respectively (19).
Although the findings of Gandini et al. (15)
were in agreement with the finding of this
study for the semen volume, they showed
no significant difference between the semen
volumes for different types of testicular tumor. The
finding of this study could suggest that even if the
differences were not significant, there were some
changes among the various groups.
The results of the semen analysis in this study
showed that more than 61% of the patients
with testicular tumor had an abnormal sperm
concentration. Also, 5% of the patients were
azoospermic. The mean of sperm concentration
in all of the patients was 23.4 × 106/ml and the
mean sperm concentration in the patients with
abnormal sperm concentration was 7.26 × 106/ml.
The findings of this study were in agreement with
all the previous studies that suggest that testicular
carcinoma diminishes the sperm concentration in
patients (20, 21). Unfortunately, proteomic study
showed defective cellular pathways in TC patients
before cancer treatment (20).
Investigating each individual group of patients,
based on their type of carcinoma, also showed
that the mean of sperm concentration in those
patients with abnormal sperm concentration, in
each group, was significantly different from the
value recommended by the WHO. This finding
is consistent with the results of Petersen et al.,
who concluded that there was a significant
difference between the sperm count in patients
with testicular carcinoma and healthy volunteers
(21).
Although there were different effects among
the various groups, the results showed that
those patients diagnosed with “other types of
tumor” such as embryonal carcinoma and yolk
sac tumor had the most severe effects on their
sperm concentration. Nevertheless, there was a
clear finding that all types of testicular carcinoma
studied could reduce the sperm concentration, as
> 61% of the patients in this study had an abnormal
sperm concentration. This finding is in agreement
with the findings of two other studies that found
that the semen quality in seminoma patients was
better than that in the other types of testicular
carcinoma (14, 15).
The results of the present study showed that
> 56% of the patients had abnormal total sperm
counts. The comparison between the various
groups did not show any significant difference
between them, which differs from the study
by Gandini et al. (15), who found a significant
difference between the total sperm counts in
a seminoma group and a group of embryonal
carcinoma.
All of the groups in the present study showed
a significant difference between their total sperm
count and that of the group of volunteers as
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a control. There was a significant difference
between the mean total sperm counts of those
patients with normal sperm counts.
The total sperm count is related to the sperm
concentration and the volume of ejaculated
semen. The result of this study showed that
although the highest percentage of the patients
with abnormal sperm concentration belonged
to the patients diagnosed with “other types of
tumor, while the seminoma group was ranked
third, seminoma had the highest percentage for
abnormal total sperm count (at 56%).
The mean of “excellent” sperm motility and
“excellent plus sluggish” sperm motility were
examined in all of the patients. Results showed
that there were no significant differences between
the groups. This does not agree with the finding
of Gandini et al. (15), who found a significant
difference between a seminoma group and an
embryonal carcinoma group, but it is consistent
with their further finding that there was no
significant difference between the seminoma
group and a groupwith mixed germ cell tumor and
was also in agreement with their observation of
no significant difference between their groups of
mixed germ cell tumor and embryonal carcinoma.
The results showed that the mean “excellent”
and “excellent plus sluggish” sperm motility, either
for all of the patients together or in the individual
groups, had a significant difference from the mean
“excellent” and “excellent plus sluggish” sperm
motility of the volunteers and from the values
recommended by the WHO. This is in agreement
the results of Botchan et al. (16), who found
that there was a significant difference between
the sperm motility of patients with testicular
carcinoma and group of healthy volunteers. Also,
the finding of the present study was in agreement
with the results of the study of Panidis et al.
(18) who found that 50% of the patients had
abnormal sperm motility and their sperm motility
was different from a group of fertile men as the
control.
Comparison between the four different groups
in the present study showed that the seminoma
group had the lowest mean of “excellent” sperm
motility and the patients with mixed germ cell
tumor had the highest mean. All of these data
suggest that patients with seminoma experienced
the greatest effect of the carcinoma on their
sperm motility. The findings of the present
study differ from those of other studies by
Gandini et al. (15) and Botchan et al. (16), which
suggested that seminoma patients had better
semen quality than patients with other testicular
carcinoma.
Among 180 zoospermic patients, only three
had nil “excellent” sperm motility and belonged
to the seminoma group. This finding supports
the suggestions that patients with seminoma had
the worst value for “excellent” sperm motility
and that this may be caused by the effects of
the carcinoma. Sperm morphology is still one
of the most controversial semen parameters in
terms of its role in evaluating potential male
fertility. As there have been very few previous
studies that have explained the influence of
testicular carcinoma on the morphology of sperm,
the discussion that follows has to be based
very largely on the findings of this present
study.
The results of the present study show that
the morphology of sperm is the most sensitive
semen parameter that is affected by testicular
https://doi.org/10.18502/ijrm.v13i7.7371 Page 547
International Journal of Reproductive BioMedicine Ghasemi et al.
carcinoma and this is in agreement with the similar
finding of Panidis et al. (18). Of the 190 patients
in the present study, who had various testicular
carcinoma, only 15 had normal spermmorphology.
Even these 15 patients with normal morphology
had a mean morphology of 18.07%, which was
significantly different from the lowest percentage
of the morphology in the group of volunteers.
This finding is in agreement with the study of
Botchan et al. (16), who found that there was a
significant difference between the normal sperm
morphology in the patients with testicular cancer
and healthy volunteers. The finding of Panidis
et al. (18) was also in agreement with the finding
of this study, as they found that 83.4% of their
patients had abnormal sperm morphology and
that there was a mean difference between their
patients with testicular cancer and normal fertile
men.
The most severe effects of testicular carcinoma
on the morphology of sperm were seen, in
the present study, in the group of patients
diagnosed with “other types of tumor”, as all of the
patients (100%) had abnormal sperm morphology
with a mean morphology of 5.23%. This is in
agreement with the finding of Gandini et al.
(15), who showed that of the three groups of
patients with testicular carcinoma, those patients
with embryonal carcinoma had the lowest value
of normal sperm morphology, being lower than
that of the seminoma patients and patients with
mixed germ cell tumors. In this latter group,
three patients (12%) had too few sperm with
normal morphology to count. The smallest effect
of testicular carcinoma on sperm morphology was
seen in the group of patients with mixed germ
cell tumors, in which < 78% of the patients had
abnormal sperm morphology, with a mean sperm
morphology of 8.5%. None of the patients had
too few normal sperm to count. All of these
findings confirm that testicular carcinoma lead
to alterations in sperm morphology and are in
agreement with all of the limited number of
previous studies (14, 16, 18, 21). Most carcinoma
appeared to seriously impair sperm morphology
in most cases.
5. Conclusion
Impaired spermatogenesis is seen in most
patients with testicular cancer before treatment
with radiation, chemotherapy, or surgery. The
causes of poor semen quality in cancer patients
are not well-recognized, but the patients with
impaired spermatogenesis should have precise
examination to find out the correct diagnosis
of problem and preserve the fertility before any
treatment. Many mechanisms contribute to the
impairment of semen, including the direct effect of
the tumor on the testes and indirect effects such
as hormones and secretions from the tumor, which
should be considered on a case-by-case basis
of male infertility. So, most carcinoma seriously
impair spermmorphology. However, it is important
to know the duration of problem, stage and
grade of tumors, which might affect the results
of evaluation. Future study should consider these
limitations of the present study.
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